Bristol-Myers staggered by a stunning checkpoint setback, hands Merck a free pass on frontline lung cancer combo
Bristol-Myers Squibb $BMY fans can scratch any hopes of an accelerated filing for a combination of Opdivo and Yervoy as a frontline therapy for lung cancer. The big biotech announced in a terse statement late Thursday that it will not pursue an accelerated approval due to the “review of data available at this time.”
More insight? Forget about it. Says Bristol-Myers:
“In order to protect the integrity of ongoing registrational studies, the company will not be providing additional details.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.